Capital World Investors Grows Stock Holdings in IQVIA Holdings Inc. $IQV

Posted by on Jun 9th, 2026

Capital World Investors boosted its position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 0.6% in the 4th quarter, Holdings Channel reports. The fund owned 594,744 shares of the medical research company’s stock after purchasing an additional 3,480 shares during the period. Capital World Investors’ holdings in IQVIA were worth $134,061,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Los Angeles Capital Management LLC boosted its holdings in shares of IQVIA by 3.5% in the 4th quarter. Los Angeles Capital Management LLC now owns 179,645 shares of the medical research company’s stock valued at $38,888,000 after purchasing an additional 6,118 shares during the last quarter. Havemeyer Place LP acquired a new position in shares of IQVIA in the 4th quarter valued at $473,000. BI Asset Management Fondsmaeglerselskab A S boosted its holdings in shares of IQVIA by 234.0% in the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 22,319 shares of the medical research company’s stock valued at $5,031,000 after purchasing an additional 15,637 shares during the last quarter. Pinebridge Investments LLC acquired a new position in shares of IQVIA in the 4th quarter valued at $10,755,000. Finally, Vise Technologies Inc. boosted its holdings in shares of IQVIA by 15.9% in the 4th quarter. Vise Technologies Inc. now owns 2,145 shares of the medical research company’s stock valued at $484,000 after purchasing an additional 294 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

NYSE:IQV opened at $183.64 on Tuesday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a market capitalization of $30.65 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 1.57 and a beta of 1.21. The firm’s fifty day simple moving average is $172.42 and its 200 day simple moving average is $194.55. IQVIA Holdings Inc. has a twelve month low of $151.58 and a twelve month high of $247.04.

IQVIA (NYSE:IQV – Get Free Report) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its board has authorized a stock buyback plan on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Mizuho set a $215.00 price target on shares of IQVIA in a report on Monday, February 23rd. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target on the stock in a report on Friday, March 6th. Truist Financial decreased their price target on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Morgan Stanley set a $225.00 price target on shares of IQVIA in a report on Thursday, May 7th. Finally, Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, IQVIA presently has an average rating of “Buy” and an average target price of $224.13.

Check Out Our Latest Research Report on IQV

IQVIA Profile

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Featured Stories

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.